Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2015

View Archived Issues

ASP-7147 shows promise in clinic for IBS-D

VPR-7 effective in murine IBD models

VBL Therapeutics discloses new drug candidate for liver fibrosis in NASH

U.S. scientists report anti-EFNA4 antibody-drug conjugates

Cypher Genomics and Celgene collaborate to discover novel genomic biomarkers

NIH extends grant to Viamet for antifungal agents for Valley fever

Baxter seeks European approval for IGSC 20% for primary immunodeficiencies

Sustained effects seen with ENV-905 Ophthalmic Implant in vivo

EMA committee recommends approval of Omidria

EMA committee hands down positive opinion for Keytruda in advanced melanoma

Merus and Selexis awarded grant to develop bispecific antibody combination products

EMA's CHMP supports approval of Repatha for high cholesterol

Stelara recommended for European approval for plaque psoriasis in adolescents

MSI-1 inhibitors block RNA binding as a new strategy for cancer treatment

Janssen to acquire license to Novo Nordisk autoimmune disease development program

Kuvan gets positive opinion from CHMP for expanded indication

Novel small-molecule disruptors of HuR-mRNA interaction show promise for cancer therapy

R-Tech Ueno completes single-dose phase I trial of RTU-1096

Bayer patents chymase inhibitors

Boehringer Ingelheim presents Brd4 inhibitors

iTeos Therapeutics discloses TDO2 inhibitors

Bristol-Myers Squibb prepares and tests GSK-3 inhibitors for Alzheimer's

Gilead Sciences patent describes development of antiviral compounds

Imbruvica recommended for European approval in Waldenstrom's macroglobulinemia

Amgen ends participation in collaboration on brodalumab development

Nivolumab receives EMA recommendation for squamous NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...